



**EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

**MINUTES OF THE MEETING HELD ON WEDNESDAY 18th JANUARY 2017
AT 12.30pm**

**IN SEMINAR ROOM 6, LEARNING & DEVELOPMENT CENTRE,
ROYAL BLACKBURN HOSPITAL**

PRESENT:

Dr D Gavan (DG)	Consultant Radiologist ELHT (Chairperson)
Dr L Rogan (LR)	Head of Medicines Commissioning NHS EL CCG
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Ms A Atkinson (AA)	Pharmacist LCFT (representing Mrs C Harding)
Dr T McKenzie (TM)	GP, EL CCG

In Attendance

Ms L Prince	Medicines Management Technician EL CCG
-------------	--

2017/001: APOLOGIES:

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr K Burch (KB)	Consultant Microbiologist ELHT
Dr S Davies (SD)	GP, EL CCG

2017/002: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2017/003: MINUTES OF DECEMBER MEETING:

Accepted as a correct record.

2017/004: MATTERS ARISING:

2016/155: Formulary Updates – Demeclocycline: LR to ask LMMG to review demeclocycline and tolvaptan.

2016/157: Generic Prescribing Position Statement – letter for patients to be issued in GP practices received & acknowledged by ELMMB.

2016/170: LMMG Consultations -Opioid Tapering and Withdrawal Guidance - to be further discussed when LMMG guidance is available.

2017/005: LMMG CONSULTATIONS (for Feb LMMG)

Guidelines for the Prescribing of Nutritional Supplements Post Bariatric Surgery

Locally a commissioning policy was developed in 2011 which is now requires review. LMMG has developed a new guideline. ELMMB found the guideline confusing with lots of stars to qualify entries on tables. It is not clear why some are recommended for prescribing and some for purchase in different groups of patients. The references appear to be from clinical guidelines rather than directly from clinical trials. ELMMB considered that a simple position statement would be more helpful to GP's.

Management of Psoriasis in Primary Care Scope

ELHT dermatology consultants suggest that the current readily available advice for the management of chronic plaque psoriasis is comprehensive and easily accessible, and are not convinced there is a need for a local guideline in addition. Primary care suggested a short, 2 page, guideline with more detail on specific products would be useful rather than a more general guideline which simply reflects what already exists. This may need to be tailored locally to reflect local commissioning pathways and formularies.

Insulin Degludec Recommendation

ELHT diabetic consultants supported the recommendation. It was suggested that it could have a green traffic light in line with other long acting insulin's.

Resolved: CW to send responses to LMMG.

2017/006: LMMG RECOMMENDATIONS (from December)

Safinamide Recommendation - LMMG guideline accepted as written for ELHE.

Traffic light: Black

Bazedoxifene & Conjugated oestrogens Recommendation – LMMG guidelines accepted as written for ELHE.

Traffic light: Black

Resolved: Recommendations accepted for ELHE as above and all to be uploaded to ELMMB website.

2017/007 FORMULARY UPDATES

Potassium citrate matrix (Urocit) tablets – changed from green to red traffic light as is unlicensed.

Sodium valproate – Guidance has been received by the CCG's from LCfT with respect to actions required on management of women of childbearing potential and referral back to specialist services in line with the MHRA advice. A response from neurology is still

awaited. ELMMB agreed to support LCfT advice for all patients due to patient safety implications. The information from LCfT will be shared with ELMMB in February prior to uploading to website.

Resolved: Formulary to be updated as above and sodium valproate information to be shared at next ELMMB.

2017/008: ELHT GUIDELINES FOR THE TREATMENT OF SMALL BOWEL BACTERIAL OVERGROWTH

Addition to secondary care antimicrobial guidelines, agreed with gastroenterology and microbiology. Approved for use.

Resolved: ELMMB approved.

2017/009: ELHT POST THYROIDECTOMY HYPOGLYCAEMIA MANAGEMENT PROTOCOL

Protocol agreed in ENT directorate for information.

Resolved: ELMMB acknowledged.

2017/010: ELHE MEDICINE SICK DAY RULES – HEALTH PROFESSIONAL LEAFLET

This briefing document adapted from Scottish patient safety programme is to guide health professionals with advice to patients on potential for dehydration with some medicines.

References to the Scottish NHS need to be omitted and included as an acknowledgement. ELMMB members asked if the patient cards would be available. LR agreed to explore possibility of procuring cards locally.

Resolved: LR to update leaflet and check availability of cards for patients.

2017/011: NICE RECOMMENDATIONS (from Dec)

Ticagrelor for preventing atherothrombotic events after myocardial infarction (TAG420) is recommended as an option by NICE. Approved in line with NICE. CCG commissioned.

Traffic Light: AMBER

Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TAG 421) is recommended as an option by NICE. Approved in line with NICE. . NHS England commissioned.

Traffic Light: RED

Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TAG 422) is recommended as an option by NICE. Approved in line with NICE. . NHS England commissioned.

Traffic Light: RED

Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TAG 423) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.

Traffic Light: RED

Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TAG 424) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.
Traffic Light: RED

Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TAG 425) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.
Traffic Light: RED

Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TAG 426) is recommended as an option by NICE. Approved in line with NICE. NHS England commissioned.
Traffic Light: RED

EXTRA ITEM

The last meeting LMMG noted that the Lancashire Collaborative Commissioning Board are considering if it is possible to move to a single decision making process across Lancashire in place of the current recommendations to CCG's.

LR suggested this would streamline and speed up the process providing there was some flexibility to accommodate local commissioning arrangements and pathways. ELMMB members expressed some concern about local clinical input and opportunities for local discussion and consultation across the health economy. LR offered to draft a discussion document outlining the new approach and local implications.

STANDING ITEMS

2017/012: FOR ACTION/INFORMATION: LANCASHIRE MEDICINES MANAGEMENT GROUP MINUTES – December 2016

Minutes acknowledged

DATE OF NEXT MEETING – Next meeting is Wednesday 15th February 2017 12.30pm, Seminar Room 7, Learning and Development Centre, RBH.

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 18TH JANUARY 2017

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2016/155	Formulary Updates – Demeclocycline – request LMMG to review demeclocycline and tolvaptan	LR	Feb 17
2017/007	Formulary Updates – Sodium valproate –information from LCfT to next meeting	LR	Feb 17
2017/010	ELHE Medicine Sick Day Rules – Health Professional Leaflet – remove reference to Scotland in body of text. Check availability of cards for patients	LR	Feb 17